Norris Medicines Stock Falls to 52-Week Low of Rs.14 Amidst Prolonged Downtrend

Recent Price Movement and Market Context

On 4 December 2025, Norris Medicines touched Rs.14, its lowest price in the past year. This level represents a notable drop from its 52-week high of Rs.24.65, indicating a decline of approximately 43.2% from that peak. The stock has been trading below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, signalling a persistent bearish trend.

Over the last two trading sessions, Norris Medicines has recorded a cumulative return of -3.58%, further extending its losing streak. On the day of the new low, the stock underperformed its sector by 0.34%, reflecting relative weakness within the Trading & Distributors industry segment.

In contrast, the broader market has shown resilience. The Sensex, after an initial negative opening, recovered to close 0.17% higher at 85,252.02 points, remaining close to its 52-week high of 86,159.02. The index is trading above its 50-day and 200-day moving averages, supported by gains in mega-cap stocks. This divergence highlights the challenges faced by Norris Medicines relative to the overall market environment.

Financial Performance and Long-Term Trends

Norris Medicines’ financial data over the past five years reveals subdued growth and persistent challenges. Net sales have shown a compound annual decline of 2.13%, while operating profit has remained flat, indicating limited expansion in core business profitability. The company’s book value is negative, which points to weak long-term fundamental strength.

Debt levels have been a concern, with the average debt-to-equity ratio reported at zero, suggesting reliance on non-equity financing or other liabilities. The company’s quarterly results for September 2025 further illustrate financial strain, with PBDIT (Profit Before Depreciation, Interest and Taxes) at a negative Rs.0.49 crore and PBT (Profit Before Tax) excluding other income at a negative Rs.0.72 crore. Earnings per share (EPS) for the quarter stood at a negative Rs.0.73, marking the lowest in recent periods.

These figures underscore the company’s ongoing difficulties in generating positive earnings and maintaining profitability, contributing to the stock’s subdued market performance.

Stock Performance Relative to Benchmarks

Over the last year, Norris Medicines has recorded a return of -38.35%, significantly lagging behind the Sensex’s 5.26% gain during the same period. This underperformance extends beyond the one-year horizon, with the stock also trailing the BSE500 index over the last three years, one year, and three months. The stock’s risk profile is elevated, with profits declining by 71% over the past year, reflecting heightened volatility and uncertainty.

The stock’s valuation metrics indicate a riskier profile compared to its historical averages, which may be a factor in the sustained downward pressure on its price.

Shareholding and Market Position

The majority of Norris Medicines’ shares are held by non-institutional investors, which may influence trading patterns and liquidity. The company operates within the Trading & Distributors sector, a segment that has seen mixed performance across its constituents. Despite the broader market’s positive momentum, Norris Medicines has not mirrored this trend, reflecting company-specific factors impacting its valuation.

With a market capitalisation grade of 4, the company is categorised within a smaller market cap bracket, which can contribute to higher price volatility and sensitivity to market developments.

Summary of Key Metrics

The stock’s 52-week low of Rs.14 contrasts sharply with its 52-week high of Rs.24.65, illustrating a wide trading range and significant price erosion. The recent two-day decline of 3.58% adds to the downward momentum. Financial results show negative EBITDA and declining profits, while sales have contracted over the medium term. The stock’s underperformance relative to the Sensex and BSE500 indices highlights its challenges in keeping pace with broader market gains.

Overall, Norris Medicines is navigating a difficult phase marked by subdued financial results and market pressures, reflected in its current valuation and trading levels.

Limited Time Only! Upgrade now and get 1 Year of Stock of the week worth Rs. 14,999 for FREE. Don't miss out on this exclusive offer. Claim Your Free Year →